1-(3-氯苯基)-3-[3-(四甲基-1,3,2-二氧杂硼硼烷-2-基)苯基]脲 | 874302-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-氯苯基)-3-[3-(四甲基-1,3,2-二氧杂硼硼烷-2-基)苯基]脲
• 英文名称: 1-(3-Chlorophenyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea
• 英文别名: 1-(3-chlorophenyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea
• CAS: 874302-01-9
• 化学式: C₁₉H₂₂BClN₂O₃
• 分子量: 372.659
• InChiKey: BYTJDHICJTWRAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.28
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-3-[3-(四甲基-1,3,2-二氧杂硼硼烷-2-基)苯基]脲 在 盐酸 、 四(三苯基膦)钯 、 水 、 sodium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 10.17h， 生成 1-(3-(3-amino-1-(4-aminobutanoyl)-1H-indazol-4-yl)phenyl)-3-(3-chlorophenyl)urea
  参考文献：
  名称：

  Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors

  摘要：

  DOI：

  10.1016/j.bioorg.2023.106439
• 作为产物：
  描述：

  3-氨基苯硼酸 在 magnesium sulfate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.33h， 生成 1-(3-氯苯基)-3-[3-(四甲基-1,3,2-二氧杂硼硼烷-2-基)苯基]脲
  参考文献：
  名称：

  Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach

  摘要：

  Pathological angiogenesis plays a critical role in numerous diseases including malignancy. VEGFR-2 is the central regulators in angiogenesis and has become a promising target for anticancer drug design. We have identified a novel biphenyl-aryl urea incorporated with salicyladoxime (BPS-7) as potent VEGFR-2 inhibitor. As a continuation to our previous research, various aromatic-heterocyclic were introduced as hinge-binding fragment via a core-refining approach. Interestingly, many compounds exhibited comparable VEGFR-2 inhibition to Sorafenib. In particular, 12e and 12o displayed excellent VEGFR-2 inhibitory activity with IC50 values of 0.50 nM and 0.79 nM, respectively. Several title compounds showed considerable antiproliferative activity against A549 and SMMC-7721 cells. In addition, molecular docking was performed to rationalize the efficiency of the better compounds. These results will be instructive for further inhibitor design and optimization. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.045

文献信息

• Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors
  作者：Ru Si、Ping Hai、Yongbiao Zheng、Nanxin Liu、Jin Wang、Qingqing Zhang、Yanchen Li、Xiaoyan Pan、Jie Zhang

  DOI：10.1016/j.bmcl.2023.129275

  日期：2023.5
• Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach
  作者：Yuanyuan Shan、Hongping Gao、Xiaowei Shao、Jinfeng Wang、Xiaoyan Pan、Jie Zhang

  DOI：10.1016/j.ejmech.2015.08.045

  日期：2015.10

  Pathological angiogenesis plays a critical role in numerous diseases including malignancy. VEGFR-2 is the central regulators in angiogenesis and has become a promising target for anticancer drug design. We have identified a novel biphenyl-aryl urea incorporated with salicyladoxime (BPS-7) as potent VEGFR-2 inhibitor. As a continuation to our previous research, various aromatic-heterocyclic were introduced as hinge-binding fragment via a core-refining approach. Interestingly, many compounds exhibited comparable VEGFR-2 inhibition to Sorafenib. In particular, 12e and 12o displayed excellent VEGFR-2 inhibitory activity with IC50 values of 0.50 nM and 0.79 nM, respectively. Several title compounds showed considerable antiproliferative activity against A549 and SMMC-7721 cells. In addition, molecular docking was performed to rationalize the efficiency of the better compounds. These results will be instructive for further inhibitor design and optimization. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors
  作者：Ru Si、Huanjie Zhu、Jin Wang、Qingqing Zhang、Yanchen Li、Xiaoyan Pan、Jie Zhang

  DOI：10.1016/j.bioorg.2023.106439

  日期：2023.5